Zhitong Finance App News, Shanghai Pharmaceutical (02607.HK) issued an announcement. Recently, Shanghai Shangyao Xinyi Pharmaceutical Co., Ltd. (hereinafter referred to as “Shangyao Xinyi”), a subsidiary of Shanghai Pharmaceutical Group Co., Ltd. (hereinafter referred to as the “Company”), received a “Drug Registration Certificate” (certificate number: 2026S02750) issued by the China Drug Administration (hereinafter referred to as the “State Drug Administration”) for omeprazole sodium bicarbonate dry suspension (I) (hereinafter referred to as “the drug”), and the drug was approved for production.

Zhitong Finance App News, Shanghai Pharmaceutical (02607.HK) issued an announcement. Recently, Shanghai Shangyao Xinyi Pharmaceutical Co., Ltd. (hereinafter referred to as “Shangyao Xinyi”), a subsidiary of Shanghai Pharmaceutical Group Co., Ltd. (hereinafter referred to as the “Company”), received a “Drug Registration Certificate” (certificate number: 2026S02750) issued by the China Drug Administration (hereinafter referred to as the “State Drug Administration”) for omeprazole sodium bicarbonate dry suspension (I) (hereinafter referred to as “the drug”), and the drug was approved for production.